stockrowCytomX Therapeutics, Inc.
CTMX Healthcare Biotechnology
CytomX Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $76.2 million, down 44.8% from fiscal 2024.
- Revenue
- −71.7%
- EPS
- 0.00%
- Free cash flow
- +204.1%
Quarter to September 2026, against a year earlier
Follow CTMX
Alert me
CytomX Therapeutics, Inc. (CTMX) EV/Sales
As of 6 November 2026, CytomX Therapeutics, Inc. (CTMX) trades at a EV/Sales of 10.9×. Over the past ten years it has ranged from −13.6× (October 2015) to 46.7× (September 2016); the current reading is higher than 84% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 6.0× | — |
| FY2024 | −0.1× | — |
| FY2023 | −0.5× | — |
| FY2022 | −1.6× | — |
| FY2021 | −0.6× | — |
| FY2020 | −0.1× | — |
| FY2019 | 1.5× | (55.27%) |
| FY2018 | 3.2× | (46.55%) |
| FY2017 | 6.1× | (55.72%) |
| FY2016 | 13.7× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 19.2× | (28.98%) |
| Jun 2026 | 27.0× | 95.52% |
| Mar 2026 | 13.8× | 131.34% |
| Dec 2025 | 6.0× | 75.26% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MNPR Monopar Therapeutics Inc. compare | n/m |
| INDP Indaptus Therapeutics, Inc. compare | n/m |
| DMAC DiaMedica Therapeutics, Inc. compare | n/m |
| MDXG MiMedx Group, Inc compare | 1.2× |
| RGNX REGENXBIO Inc. compare | 1.6× |
| CTMX CytomX Therapeutics, Inc. | 10.9× |
| STTK Shattuck Labs, Inc. compare | 69.1× |
| CBIO Crescent Biopharma, Inc. compare | 228× |
| ETRA Electra Therapeutics Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)